With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
Publication|Articles|August 12, 2024
- Pharmaceutical Commerce - August 2024
- Volume 19
- Issue 4
Pharmaceutical Commerce - August 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Commerce August 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 2 years ago
Taking Inventoryabout 2 years ago
A Journey of the Mindabout 2 years ago
Pharmacy Deserts are Becoming a National Problemabout 2 years ago
An Examination of Big Pharma Inventoriesabout 2 years ago
The IRA’s Impact on Patient Hub, Access, and Affordability Programsabout 2 years ago
US Drug Wholesaling 2024: Staying the Courseabout 2 years ago
Biotech’s Achilles’ Heelabout 2 years ago
Looking Ahead to Medicare Reforms Coming in 2025Advertisement
Related to this article
As patient expectations continue to evolve, brick-and-mortar pharmacy’s path forward lies in combining trusted, face-to-face care with the efficiency and convenience patients increasingly value.
Copeland's Dickson buy adds cloud-native monitoring as the pharma cold chain moves toward continuous visibility to meet rising regulatory demands.
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
Cencora's Ameer Ali on the operational lift behind the 12-digit NDC shift, the readiness gap across manufacturers and what's at stake for product flow if systems aren't ready in time.
Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes.
Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Supply Chain Signal: How Policy Pressures Are Converging on Pharma
2
FAQ: What Comes Next for the 340B Rebate Pilot
3
Pharma Pulse: Vicapsys-Stateline Merger and Veritiv's TempSafe RxShield
4
Copeland Closes Dickson Deal to Expand Cold Chain Monitoring
5